Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Continuous Versus Intermittent Vancomycin Infusions in Infants: A Randomized Controlled Trial
Amanda Gwee1,2,3, Noel Cranswick4,2,3, Brendan McMullan5,6
1Department of Paediatrics, The University of Melbourne, Parkville, Australia; amanda.gwee@rch.org.au.
Insights
Continuous vancomycin infusions (CIV) in young infants achieve target concentrations faster and require lower doses than intermittent infusions (IIV). Both methods showed no significant drug-related adverse effects, making CIV a potentially more effective option.
Area of Science:
- Neonatal pharmacology
- Pediatric infectious diseases
- Clinical pharmacy
Background:
- Continuous infusions of vancomycin (CIV) in adults offer advantages in achieving therapeutic drug levels and potentially reducing toxicity.
- The efficacy and safety of CIV versus intermittent vancomycin infusions (IIV) in young infants remain less understood.
- Optimizing vancomycin dosing in neonates is critical due to their unique pharmacokinetic profiles.
Purpose of the Study:
- To compare the effectiveness of continuous vancomycin infusions (CIV) versus intermittent vancomycin infusions (IIV) in young infants.
- To determine which infusion method achieves target vancomycin concentrations at the first steady-state level more efficiently.
- To compare the incidence of drug-related adverse effects between CIV and IIV in this population.
Main Methods:
- A multicenter randomized controlled trial was conducted in two tertiary neonatal units.
- Young infants (0-90 days) requiring vancomycin therapy for at least 48 hours were randomized to either CIV or IIV.
- The primary outcome was the proportion of infants achieving target vancomycin concentrations at the first steady-state level.
Main Results:
- Continuous vancomycin infusions (CIV) resulted in a significantly higher proportion of infants achieving target concentrations (85% vs. 41%, P < .001).
- Fewer dose adjustments were needed with CIV, and the mean daily dose to reach target levels was lower compared to IIV (40.6 vs. 60.6 mg/kg/day, P = .01).
- No drug-related adverse effects were observed in either the CIV or IIV groups.
Conclusions:
- Continuous vancomycin infusions (CIV) are more effective than intermittent vancomycin infusions (IIV) in young infants for achieving target drug concentrations earlier.
- CIV requires lower total daily doses to reach therapeutic vancomycin levels in neonates.
- Both CIV and IIV demonstrate comparable safety profiles with no drug-related adverse effects in this study population.
Background:
In adults, continuous infusions of vancomycin (CIV) are associated with earlier attainment of target drug concentrations, require fewer blood samples for monitoring, and may reduce drug toxicity. We aimed to determine, in young infants, if CIV or intermittent infusions of vancomycin (IIV) better achieves target vancomycin concentrations at the first steady-state level and to compare the frequency of drug-related adverse effects.
Methods:
In a multicenter randomized controlled trial in 2 tertiary neonatal units over a 40-month period, young infants aged 0 to 90 days requiring vancomycin therapy for at least 48 hours were randomly assigned to CIV and IIV.
Results:
Of 111 infants randomized, 104 were included in the intention-to-treat analysis. Baseline characteristics were similar for both groups. The proportion of infants achieving target concentrations at the first steady-state level was higher for CIV compared with IIV (45 in 53 [85%] vs 21 in 51 [41%]; P < .001). Fewer dose adjustments were required in the CIV group (median 0; range 0-1) compared with the IIV group (median 1; range 0-3; P < .001). The mean daily dose required to achieve target concentrations was lower with CIV compared with IIV (40.6 [SD 10.7] vs 60.6 [SD 53.0] mg/kg per day, respectively; P = .01). No drug-related adverse effects occurred in either group.
Conclusions:
In young infants, CIV is associated with earlier and improved attainment of target concentrations compared with IIV. Lower total daily doses are required to achieve target levels with CIV. There is no difference in the rate of drug-related adverse effects.
More Related Videos
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Random Error
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...

